Scientist I, In Vivo Pharmacology – Discovery Biology - San Francisco, CA | Biospace
Get Our FREE Industry eNewsletter

Scientist I, In Vivo Pharmacology – Discovery Biology

Nurix, Inc.

San Francisco, CA
Posted Date:
Position Type:
Full time
Job Code:
Required Education:
Areas of Expertise Desired:
Biology, Biotechnology, Cancer, Immunology, In Vivo, PhD,

Job Description

We are seeking a highly skilled and motivated in vivo pharmacologist to support Nurix’s mission of targeting E3 ubiquitin ligases in the areas of oncology and immunology. The ideal candidate will have expertise in small molecule PK/PD studies in oncology and/or immuno-oncology.

Primary Functions

This individual will work closely with our drug discovery project scientists on late-stage lead optimization of novel compounds to evaluate PK/PD relationships, in vivo efficacy and ex vivo immune cell function. The candidate must be self-driven, organized, able to work well with project scientists, and able to thrive in an exciting environment in a rapidly-growing company.



Ph.D. in immunology, cancer biology or related field with 0-3 years of industry experience

Expertise in the in vivo evaluation of small molecules, PK/PD assay technologies, and hit-to-lead optimization required

In vivo pharmacology expertise with xenograft or syngeneic tumor models required

Excellent hands-on in vivo skills: IV, PO dosing, tumor implantation, blood/tissue collection, etc.

Proven ability to manage junior scientists, external collaborations, and CROs

Experience with FACS-based characterization of immunity preferred

Novel in vivo model experience is a plus (e.g., CRISPR or humanized immune system mice)

Excellent communication and presentation skills

Excellent interpersonal skills and ability to work productively in a highly dynamic environment

Fit with Nurix Culture and Values:

Team orientation; highly collaborative; solutions and results-oriented focus

Strong scientific curiosity and initiative; hands-on and resourceful

Self-driven and enthusiastic with the ability to thrive in a dynamic environment


Nurix, Inc. is a science-focused and goal-oriented organization that is committed to bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating E3 ubiquitin ligases within the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. The Nurix scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the UPS, enabling the development of new class of drugs that can restore normal cellular homeostasis. Nurix was founded by internationally-recognized experts in the UPS field and received its initial funding from leading life science investors, Third Rock Ventures and The Column Group. The Company recently entered into a multi-year strategic collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation; including the rapidly evolving field of immuno-oncology. Nurix is based in San Francisco, California.